TABLE OF CONTENTS
1 INTRODUCTION 68
1.1 OBJECTIVES OF THE STUDY 68
1.2 MARKET DEFINITION 68
1.3 OVERVIEW 68
1.4 CURRENCY AND PRICING 70
1.5 LIMITATIONS 70
1.6 MARKETS COVERED 71
2 MARKET SEGMENTATION 74
2.1 MARKETS COVERED 74
2.2 GEOGRAPHICAL SCOPE 75
2.3 YEARS CONSIDERED FOR THE STUDY 76
2.4 DBMR TRIPOD DATA VALIDATION MODEL 77
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 80
2.6 MULTIVARIATE MODELLING 81
2.7 MARKET APPLICATION COVERAGE GRID 82
2.8 PRODUCT LIFELINE CURVE 83
2.9 DBMR MARKET POSITION GRID 84
2.10 VENDOR SHARE ANALYSIS 86
2.11 SECONDARY SOURCES 87
2.12 ASSUMPTIONS 87
3 EXECUTIVE SUMMARY 88
4 PREMIUM INSIGHTS 91
4.1 PORTERS FIVE FORCES 92
4.2 PESTEL ANALYSIS 93
4.3 INDUSTRY INSIGHTS 94
4.4 CONCLUSION 95
5 ASIA PACIFIC FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: REGULATORY FRAMEWORK 96
6 MARKET OVERVIEW 98
6.1 DRIVERS 100
6.1.1 GROWING BURDEN OF GENETIC DISORDERS AS WELL AS CANCER 100
6.1.2 INNOVATION AND ADVANCEMENTS IN FISH PRODUCTS 100
6.1.3 HIGH FUNDING FOR RESEARCH ACTIVITIES 101
6.1.4 RISING DEMAND AND USAGE OF FISH TECHNIQUES 101
6.2 RESTRAINTS 102
6.2.1 HIGH COST OF FISH TESTING 102
6.2.2 LIMITED AVAILABILITY OF SKILLED PROFESSIONALS 102
6.3 OPPORTUNITIES 103
6.3.1 RISING PUBLIC AWARENESS ABOUT THE EARLY DETECTION OF GENETIC ABNORMALITIES 103
6.3.2 RISE IN DEVELOPMENT OF SPECIFIC BIOMARKERS AND VARIOUS PROBES 103
6.4 CHALLENGES 104
6.4.1 STRINGENT GOVERNMENT REGULATIONS FOR THE APPROVAL OF FISH PROBES 104
6.4.2 ETHICAL CONCERNS ASSOCIATED WITH FISH TECHNOLOGY 104
7 ASIA PACIFIC FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE 105
7.1 OVERVIEW 106
7.2 CONSUMABLES 109
7.2.1 FISH PROBE 109
7.2.1.1 FISH PROBE, BY PROBE TYPE 110
7.2.1.1.1 CHROMOSOME FISH PROBE 110
7.2.1.1.2 SPLIT FISH PROBES 110
7.2.1.1.3 TRANSLOCATION FISH PROBES 110
7.2.1.1.4 SUBTELOMERE FISH PROBES 110
7.2.1.1.5 PRENATAL FISH PROBES 110
7.2.1.1.6 OTHERS PROBES 111
7.2.1.2 FISH PROBE, BY TECHNOLOGY 111
7.2.1.2.1 FLOW FLUORESCENT IN SITU HYBRIDIZATION 111
7.2.1.2.2 C-ISH 111
7.2.1.2.3 D-ISH 111
7.2.1.2.4 Q- FLUORESCENT IN SITU HYBRIDIZATION 111
7.2.1.2.5 OTHERS 111
7.2.1.3 FISH PROBE, BY TYPE 112
7.2.1.3.1 RNA 112
7.2.1.3.1.1 MRNA 112
7.2.1.3.1.2 MIRNA 112
7.2.1.3.1.3 OTHERS 113
7.2.1.3.2 DNA 113
7.2.2 ACCESSORY KITS & REAGENTS 113
7.2.2.1 KITS 113
7.2.2.2 BUFFER 113
7.2.2.3 DYES 113
7.2.2.4 OTHERS 114
7.3 INSTRUMENT 114
7.3.1 STANDALONE 115
7.3.2 PORTABLE 115
7.3.3 HANDHELD 115
7.4 SOFTWARE 115
8 ASIA PACIFIC FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY 116
8.1 OVERVIEW 117
8.2 RNA FLUORESCENT IN SITU HYBRIDIZATION 120
8.3 DNA FLUORESCENT IN SITU HYBRIDIZATION 121
8.4 PNA FLUORESCENT IN SITU HYBRIDIZATION 122
8.5 OTHERS 123
9 ASIA PACIFIC FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION 124
9.1 OVERVIEW 125
9.2 CANCER RESEARCH 128
9.2.1 CANCER RESEARCH, BY CANCER TYPE 129
9.2.1.1 NON-HEMATOPOETIC MALIGNANCIES (SOLID TUMORS) 129
9.2.1.1.1 BREAST CANCER 129
9.2.1.1.2 LUNG CANCER 129
9.2.1.1.3 MELANOMA 130
9.2.1.1.4 PROSTRATE CANCER 130
9.2.1.1.5 OVARIAN CANCER 130
9.2.1.1.6 OTHERS 130
9.2.1.2 HEMATOPOETIC MALIGNANCIES 130
9.2.1.2.1 LEUKEMIA 130
9.2.1.2.2 MULTIPLE MYELOMA 131
9.2.1.2.3 MYELODYSPLASTIC SYNDROMES (MDS) 131
9.2.2 CANCER RESEARCH, BY PRODUCT 131
9.2.2.1 CONSUMABLES 131
9.2.2.2 INSTRUMENTS 131
9.2.2.3 SOFTWARE 131
9.3 GENETIC RESEARCH 132
9.3.1 CYTOGENETICS 133
9.3.2 CHROMOSOMAL ABNORMALITIES 133
9.3.3 OTHERS 133
9.4 INFECTIOUS DISEASE 133
9.4.1 CONSUMABLES 134
9.4.2 INSTRUMENTS 134
9.4.3 SOFTWARE 134
9.5 PERSONALIZED MEDICINE 134
9.6 OTHERS 135
10 ASIA PACIFIC FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE 136
10.1 OVERVIEW 137
10.2 RESEARCH 140
10.2.1 INSTRUMENTS 140
10.2.2 CONSUMABLES 141
10.2.3 SOFTWARE 141
10.3 CLINICAL 141
10.3.1 CONSUMABLES 142
10.3.2 INSTRUMENT 142
10.3.3 SOFTWARE 142
10.4 COMPANION DIAGNOSTIC 142
10.4.1 CONSUMABLES 143
10.4.2 INSTRUMENT 143
10.4.3 SOFTWARE 143
11 ASIA PACIFIC FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY END USER 144
11.1 OVERVIEW 145
11.2 DIAGNOSTIC LABORATORIES 148
11.3 HOSPITALS & CLINICS 148
11.4 PHARMACEUTICALS & BIOTECHNOLOGICAL COMPANIES 149
11.5 ACADEMIC & RESEARCH INSTITUTES 150
11.6 CONTRACT RESEARCH ORGANIZATIONS 150
11.7 OTHERS 151
12 ASIA PACIFIC FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY DISTRIBUTION CHANNEL 152
12.1 OVERVIEW 153
12.2 RETAIL SALES 156
12.3 ONLINE SALES 156
12.4 DIRECT TENDER 157
12.5 OTHERS 158
13 ASIA PACIFIC FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION 159
13.1 ASIA-PACIFIC 160
13.1.1 JAPAN 174
13.1.2 CHINA 182
13.1.3 SOUTH KOREA 190
13.1.4 INDIA 198
13.1.5 SINGAPORE 206
13.1.6 THAILAND 214
13.1.7 INDONESIA 223
13.1.8 MALAYSIA 231
13.1.9 PHILIPPINES 239
13.1.10 AUSTRALIA 247
13.1.11 NEW ZEALAND 255
13.1.12 VIETNAM 263
13.1.13 TAIWAN 271
13.1.14 REST OF ASIA-PACIFIC 279
14 ASIA PACIFIC FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, COMPANY LANDSCAPE 280
14.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC 280
15 SWOT ANALYSIS 281
16 COMPANY PROFILE 282
16.1 MERCK KGAA 282
16.1.1 COMPANY SNAPSHOT 282
16.1.2 REVENUE ANALYSIS 282
16.1.3 COMPANY SHARE ANALYSIS 283
16.1.4 PRODUCT PORTFOLIO 283
16.1.5 RECENT DEVELOPMENT 283
16.2 ABBOTT 284
16.2.1 COMPANY SNAPSHOT 284
16.2.2 REVENUE ANALYSIS 284
16.2.3 COMPANY SHARE ANALYSIS 285
16.2.4 PRODUCT PORTFOLIO 285
16.2.5 RECENT DEVELOPMENT 286
16.3 AGILENT TECHNOLOGIES, INC. 287
16.3.1 COMPANY SNAPSHOT 287
16.3.2 REVENUE ANALYSIS 287
16.3.3 COMPANY SHARE ANALYSIS 288
16.3.4 PRODUCT PORTFOLIO 288
16.3.5 RECENT DEVELOPMENT 288
16.4 F. HOFFMANN-LA ROCHE LTD. 289
16.4.1 COMPANY SNAPSHOT 289
16.4.2 REVENUE ANALYSIS 289
16.4.3 COMPANY SHARE ANALYSIS 290
16.4.4 PRODUCT PORTFOLIO 290
16.4.5 RECENT DEVELOPMENT 290
16.5 THERMO FISCHER SCIENTIFIC INC. 291
16.5.1 COMPANY SNAPSHOT 291
16.5.2 REVENUE ANALYSIS 291
16.5.3 COMPANY SHARE ANALYSIS 292
16.5.4 PRODUCT PORTFOLIO 292
16.5.5 RECENT DEVELOPMENT 293
16.6 ABCAM PLC. 294
16.6.1 COMPANY SNAPSHOT 294
16.6.2 REVENUE ANALYSIS 294
16.6.3 COMPANY SHARE ANALYSIS 295
16.6.4 PRODUCT PORTFOLIO 295
16.6.5 RECENT DEVELOPMENTS 295
16.7 ABNOVA CORPORATION 297
16.7.1 COMPANY SNAPSHOT 297
16.7.2 PRODUCT PORTFOLIO 297
16.7.3 RECENT DEVELOPMENT 297
16.8 BIO SB 298
16.8.1 COMPANY SNAPSHOT 298
16.8.2 PRODUCT PORTFOLIO 298
16.8.3 RECENT DEVELOPMENT 298
16.9 BIOCARE MEDICAL, LLC 299
16.9.1 COMPANY SNAPSHOT 299
16.9.2 PRODUCT PORTFOLIO 299
16.9.3 RECENT DEVELOPMENT 300
16.10 BIOCAT GMBH 301
16.10.1 COMPANY SNAPSHOT 301
16.10.2 PRODUCT PORTFOLIO 301
16.10.3 RECENT DEVELOPMENT 302
16.11 BIODOT 303
16.11.1 COMPANY SNAPSHOT 303
16.11.2 PRODUCT PORTFOLIO 303
16.11.3 RECENT DEVELOPMENT 303
16.12 BIOGENEX 304
16.12.1 COMPANY SNAPSHOT 304
16.12.2 PRODUCT PORTFOLIO 304
16.12.3 RECENT DEVELOPMENT 304
16.13 BIO-TECHNE 305
16.13.1 COMPANY SNAPSHOT 305
16.13.2 REVENUE ANALYSIS 305
16.13.3 COMPANY SHARE ANALYSIS 306
16.13.4 PRODUCT PORTFOLIO 306
16.13.5 RECENT DEVELOPMENT 306
16.14 BIOZOL DIAGNOSTICS VERTRIEB GMBH 307
16.14.1 COMPANY SNAPSHOT 307
16.14.2 PRODUCT PORTFOLIO 307
16.14.3 RECENT DEVELOPMENT 308
16.15 EXCILONE 309
16.15.1 COMPANY SNAPSHOT 309
16.15.2 PRODUCT PORTFOLIO 309
16.15.3 RECENT DEVELOPMENT 309
16.16 GENEMED BIOTECHNOLOGIES, INC. 310
16.16.1 COMPANY SNAPSHOT 310
16.16.2 PRODUCT PORTFOLIO 310
16.16.3 RECENT DEVELOPMENT 310
16.17 KANEKA EUROGENTEC S.A. 311
16.17.1 COMPANY SNAPSHOT 311
16.17.2 PRODUCT PORTFOLIO 311
16.17.3 RECENT DEVELOPMENT 311
16.18 LEICA BIOSYSTEMS NUSSLOCH GMBH 312
16.18.1 COMPANY SNAPSHOT 312
16.18.2 PRODUCT PORTFOLIO 312
16.18.3 RECENT DEVELOPMENT 312
16.19 METASYSTEMS 313
16.19.1 COMPANY SNAPSHOT 313
16.19.2 PRODUCT PORTFOLIO 313
16.19.3 RECENT DEVELOPMENT 313

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.